QOL Medical Selects Optum Frontier Therapies as New Partner for Sucraid®

QOL Medical, LLC, a rare disease pharmaceutical company, selected Optum Frontier Therapies as its new pharmacy partner to support CSID patients nationwide being treated with Sucraid® (sacrosidase) Oral Solution.

Currently, Sucraid® (sacrosidase) Oral Solution is the only treatment for Congenital Sucrase-Isomaltase Deficiency (CSID) in children and adults. Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency.

People with CSID, commonly known as Sucrose (sugar) Intolerance, are unable to properly digest sucrose (table sugar), which is found in foods like ice cream, apples, cake, and corn.

QOL Medical is a specialty biopharmaceutical company dedicated to improving clinical outcomes and overall quality of life for patients with rare diseases. QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan and gastrointestinal products in underserved markets.

Optum Frontier Therapies, a specialty pharmacy and distribution business dedicated to people with rare disease, partners with stakeholders across health care to provide customizable pharmacy and patient services, distribute and dispense specialty medications, and utilize data reporting and analytics to advance therapeutic outcomes and experiences.

QOL Medical LLC announced a partnership with US Bioservices as the exclusive Sucraid® specialty pharmacy starting mid-November 2017. All prescriptions of Sucraid® (sacrosidase) Oral Solution were to be filled and distributed exclusively by US Bioservices at the time.

Optum® Frontier Therapies has two distinct centers of expertise to tailor to the needs of a specific disease state or therapy: The Optum Frontier Therapies Center for Rare Disease and The Optum Frontier Therapies Center for Gene Therapy.

In 2021, Albireo selected Optum Frontier Therapies as a limited pharmacy partner for new drug Bylvay™. The drug was approved by the FDA for the treatment of progressive familial intrahepatic cholestasis (PFIC), a rare disorder affecting children that causes life-threatening liver disease. For those with PFIC and other rare diseases, it may be the first time they have access to breakthrough therapies with no other treatment options.


Takeaway: Optum® Frontier Therapies was founded to optimize every aspect of advanced therapeutics, from the point of prescribing to treatment and beyond